Relenza (zanamivir) — CareFirst (Caremark)
prophylaxis of influenza A or B viral infection during community outbreak
Initial criteria
- Authorization may be granted when ONE of the following criteria are met:
 - The requested drug is being prescribed for ANY of the following:
 - • Treatment of acute uncomplicated influenza in a patient age ≥ 5 years who is otherwise healthy or at high risk of developing influenza-related complications, OR post-exposure prophylaxis of influenza in a patient age ≥ 5 years and the request is for Xofluza (baloxavir marboxil).
 - • Prophylaxis of influenza A or B viral infection in a patient age ≥ 3 months during a community outbreak and the request is for Tamiflu (oseltamivir).
 - • Prophylaxis of influenza A or B viral infection in a patient age ≥ 5 years during a community outbreak and the request is for Relenza (zanamivir).
 - • The requested drug (Tamiflu or Relenza) is being prescribed for the prophylaxis or treatment of influenza A or B viral infection.
 
Approval duration
3 months